Katja Schulze

Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study

Funda Meric‐Bernstam, Herbert I. Hurwitz, Kanwal Raghav et al. · The Lancet Oncology · 2019 · 564 citations

Medicine, Oncology, Pharmacology +14

Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study

Milind Javle, Mitesh J. Borad, Nilofer S. Azad et al. · The Lancet Oncology · 2021 · 406 citations

Medicine, Oncology, Pharmacology +13

Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer

Marcelo V. Negrão, Ferdinandos Skoulidis, Meagan Montesion et al. · Journal for ImmunoTherapy of Cancer · 2021 · 292 citations · Full text

Medicine, Molecular Medicine, Oncology +17

Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial

Jamie E. Chaft, Filiz Öezkan, Mark G. Kris et al. · Nature Medicine · 2022 · 237 citations · Full text

Medicine, Oncology, Pharmacology +17

Regional Brain Morphometry in Patients With Schizophrenia or Bipolar Disorder and Their Unaffected Relatives

Colm McDonald, Nicolette Marshall, Pak C. Sham et al. · American Journal of Psychiatry · 2006 · 227 citations

Medicine, Neuroscience, Psychiatry +17